---
title: "Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/296473514.md"
description: "Recursion, Novavax, and CRISPR Therapeutics stocks declined slightly in pre-market trading on Thursday after surging the previous day. The prior rally was driven by positive Phase 3 trial results for Merck and Moderna's mRNA cancer therapy. Additionally, Recursion faced specific pressure as a former director disclosed plans to sell shares."
datetime: "2026-08-20T09:59:10.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/296473514.md)
  - [en](https://longbridge.com/en/news/296473514.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/296473514.md)
generator: "portal-rs"
---

# Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why

**Recursion Pharmaceuticals Inc.** (NASDAQ:RXRX), **Novavax Inc.** (NASDAQ:NVAX) and **CRISPR Therapeutics AG** (NASDAQ:CRSP) are trending on Thursday.

In pre-market trading, RXRX fell 1.42% to $3.45, CRSP dropped 0.15% to $59.72 and NVAX slipped 0.11% to $8.78.

## **Cancer Therapy Breakthrough Sparks Sector-Wide Rally**

The surge follows **Merck & Co. Inc.** (NYSE:MRK) and **Moderna Inc.**‘s (NASDAQ:MRNA) Wednesday pre-market announcement of positive Phase 3 results for intismeran autogene, an individualized mRNA cancer therapy, combined with KEYTRUDA. 

The trial, involving 1,137 melanoma patients, marked the first positive Phase 3 data for a neoantigen-based mRNA cancer treatment, according to the companies.

## **Recursion Draws Company-Specific Attention**

Apart from the broader sector news, RXRX had its own catalyst. In a Wednesday **Securities and Exchange Commission** filing, former Recursion director **Christopher C. Gibson** disclosed plans to sell 100,000 Class A shares, worth roughly $327,500, through brokerage firm **Fidelity Brokerage Services LLC**. 

Gibson has sold shares regularly since May.

## **Trading Metrics**

| Stock         | Market Cap    | 52-Week Range | YTD Performance |
| ------------- | ------------- | ------------- | --------------- |
| $1.45 Billion | $6.20–$11.97  | +23.28%       |                 |
| $5.78 Billion | $44.12–$78.48 | +11.23%       |                 |
| $1.87 Billion | $2.77–$7.18   | -16.67%       |                 |

On Wednesday, RXRX closed up 13.27% at $3.50, NVAX gained 10.84% to $8.79 and CRSP rose 12.91% to $59.81, according to Benzinga Pro data.

**Benzinga’s Edge Stock Rankings** indicate RXRX stock has a negative price trend across all time frames.

***Disclaimer:*** *This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.*

 **Read Also: Beam Global (BEEM) Stock Jumps Over 26% After Hours: Why Is It Trending** 

*Photo courtesy: Spyro the Dragon on Shutterstock*

### Related Stocks

- [CRSP.US](https://longbridge.com/en/quote/CRSP.US.md)
- [MRK.US](https://longbridge.com/en/quote/MRK.US.md)
- [MRNA.US](https://longbridge.com/en/quote/MRNA.US.md)
- [NVAX.US](https://longbridge.com/en/quote/NVAX.US.md)
- [RXRX.US](https://longbridge.com/en/quote/RXRX.US.md)
- [MRNX.US](https://longbridge.com/en/quote/MRNX.US.md)
- [MRNY.US](https://longbridge.com/en/quote/MRNY.US.md)
- [BEEM.US](https://longbridge.com/en/quote/BEEM.US.md)
- [SSTK.US](https://longbridge.com/en/quote/SSTK.US.md)

## Related News & Research

- [Moderna shares surge after it says its experimental mRNA cancer treatment passed a key test](https://longbridge.com/en/news/296382081.md)
- [Moderna's personalized mRNA shot could reshape the fight against skin cancer - but it may also be overhyped](https://longbridge.com/en/news/296527593.md)
- [Moderna surges on trial win for cancer shot; William Blair upgrades](https://longbridge.com/en/news/296370751.md)
- [Why Iovance Biotherapeutics Stock Hit 52-Week High](https://longbridge.com/en/news/296522969.md)
- [Health care roundup: Market talk](https://longbridge.com/en/news/296381776.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**